Can You Take Semaglutide for Weight Loss in the UK?

The biggest myth worth setting aside first

A lot of people arrive at this question assuming semaglutide is for a specific type of person, someone with a very high BMI, or severe health complications, or who has exhausted every other option. That picture is outdated. The licensed eligibility for Wegovy covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol, prediabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. That is a wide group, and it includes people who may not think of themselves as candidates at all. It is also worth saying quietly: BMI alone does not tell the whole story. A prescriber looks at the full picture (your medical history, any medicines you already take, your circumstances) before deciding whether semaglutide is appropriate for you. The number on a chart is the starting point, not the answer.

The NHS semaglutide medicines page sets out the licensed uses and the groups for whom caution is needed, and it is worth a read before or after your consultation.

How semaglutide is actually taken, injection and tablet

If you take semaglutide as Wegovy injection, it is a once-weekly subcutaneous injection into the abdomen, thigh or upper arm, using a pre-filled pen. Treatment starts at a low dose to let your body adjust, then moves through a gradual schedule over several months toward the maintenance dose. Your prescriber manages that progression; you do not change doses on your own. How often you inject, and when to move up a step, are questions that belong in that conversation, and if you are ever unsure about timing, our guide on late doses covers what the clinical guidance says.

The Wegovy tablet, approved by the MHRA in June 2026, is taken once daily first thing in the morning on an empty stomach, with a small amount of plain water. You wait at least 30 minutes before food, other drinks or any other oral medicines. No refrigeration required, one practical difference that matters to people who travel frequently or find keeping a pen cold a nuisance. The maintenance dose for the tablet is 25mg daily, reached gradually over several months. A separate question worth checking: what not to take alongside semaglutide, because a handful of interactions are worth knowing about before you start.

What the evidence says about weight loss on semaglutide

In the STEP 1 clinical trial (68 weeks, semaglutide 2.4mg weekly injection against placebo, published in the New England Journal of Medicine) participants lost around 15% of their body weight on average. The newer 7.2mg dose, approved for the injection pen in April 2026, produced roughly 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide. For the oral tablet, the OASIS 4 trial reported approximately 13.6% average weight loss over 64 weeks; among those who stayed fully adherent throughout, that figure was closer to 17%. These are averages from clinical conditions with structured lifestyle support alongside them, individual results depend on many factors, which is exactly why a prescriber's input matters. The semaglutide overview goes deeper on the evidence if you want more detail.

Side effects and what to keep an eye on

The most commonly reported side effects are gastrointestinal: nausea, diarrhoea, constipation, indigestion and burping tend to be most noticeable at the start of treatment or after a dose increase, then settle for most people within a couple of weeks. Fatigue and mild headaches are also reported. Serious but less frequent effects include pancreatitis (the MHRA has highlighted severe, persistent stomach pain that radiates to the back as a symptom warranting urgent medical attention) as well as gallbladder-related symptoms and allergic reactions. If any of these arise, stopping treatment and seeking medical help promptly is the right call. Suspected side effects can be reported through the MHRA Yellow Card scheme, which also accepts reports about any medicines you believe are counterfeit or sold improperly. Semaglutide is not recommended during pregnancy, while breastfeeding or when trying to conceive, and it is not licensed for anyone under 18. For men wondering whether the experience or eligibility differs by sex, our page on semaglutide for men covers what the evidence shows.

If you are weighing up private options and want context on how cost compares across providers, the Wegovy price comparison page lays out the UK market honestly. When you are ready to talk through whether semaglutide suits your situation, speak to our prescribers through a free consultation, reviewed by a real clinician the same day, no waiting list.